



Sen. Dan Kotowski

**Filed: 4/11/2011**

09700SB0670sam001

LRB097 04433 CEL 54208 a

1 AMENDMENT TO SENATE BILL 670

2 AMENDMENT NO. \_\_\_\_\_. Amend Senate Bill 670 by replacing  
3 everything after the enacting clause with the following:

4 "Section 5. The Pharmacy Practice Act is amended by  
5 changing Section 26 as follows:

6 (225 ILCS 85/26)

7 (Section scheduled to be repealed on January 1, 2018)

8 Sec. 26. Anti-epileptic drug product selection prohibited.

9 (a) The General Assembly finds that this Section is  
10 necessary for the immediate preservation of the public peace,  
11 health, and safety.

12 (b) In this Section:

13 "Anti-epileptic drug" means (i) any drug prescribed for the  
14 treatment of epilepsy or (ii) a drug used to treat or prevent  
15 seizures.

16 "Epilepsy" means a neurological condition characterized by

1 recurrent seizures.

2 "Seizure" means a brief disturbance in the electrical  
3 activity of the brain.

4 (c) When the prescribing physician has indicated on the  
5 original prescription "may not substitute", a pharmacist may  
6 not interchange an anti-epileptic drug or formulation of an  
7 anti-epileptic drug for the treatment of epilepsy without  
8 notification and the documented consent of the prescribing  
9 physician and the patient or the patient's parent, legal  
10 guardian, or spouse. This Section does not apply to medication  
11 orders issued for anti-epileptic drugs for any in-patient care  
12 in a licensed hospital.

13 (d) If a pharmacist substitutes any generic prescription in  
14 place of a brand-name anti-epileptic drug, then the pharmacist  
15 shall provide written notice to the patient no later than the  
16 time the prescription is dispensed.

17 (Source: P.A. 94-936, eff. 6-26-06; 95-689, eff. 10-29-07.)".